[(E)-4-hydroxy-3-methylbut-2-enyl] dihydrogen phosphate

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: [(E)-4-hydroxy-3-methylbut-2-enyl] dihydrogen phosphate
• 化学式: C₅H₁₁O₅P
• 分子量: 182.113
• InChiKey: BGLDNQQSMLYFSG-GORDUTHDSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.3
• 重原子数：
  11
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  87
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  [(E)-4-hydroxy-3-methylbut-2-enyl] dihydrogen phosphate 、 三乙胺 在 1,8-二氮杂双环[5.4.0]十一碳-7-烯 作用下， 以 四氢呋喃 为溶剂， 以76 %的产率得到triethylammonium (E)-4-hydroxy-3-methylbut-2-en-1-yl hydrogen phosphate
  参考文献：
  名称：

  [EN] CONJUGATES COMPRISING PHOSPHOANTIGENS AND THEIR USE IN THERAPY
  [FR] CONJUGUÉS COMPRENANT DES PHOSPHOANTIGÈNES ET LEUR UTILISATION À DES FINS THÉRAPEUTIQUES

  摘要：

  The present invention relates to novel conjugates comprising a targeting moiety linked to a phosphoantigen moiety, and the use thereof in the treatment of diseases, such as cancer, infectious diseases and autoimmune diseases, optionally in combination with other therapeutic agents. A targeting moiety may be an antibody, or binding fragment thereof. The phosphoantigen may be a prodrug. The invention further relates to linker-drug compounds comprising a phosphoantigen moiety, for use in the manufacture of conjugates, and pharmaceutical compositions comprising said immunoconjugates.

  公开号：

  WO2023275025A1
• 作为产物：
  描述：

  (E)-bis((9H-fluoren-9-yl)methyl) (4-((tert-butyldiphenylsilyl)oxy)-3-methylbut-2-en-1-yl) phosphate 在 吡啶 、 氟化氢吡啶 作用下， 以 四氢呋喃 为溶剂， 以66 %的产率得到[(E)-4-hydroxy-3-methylbut-2-enyl] dihydrogen phosphate
  参考文献：
  名称：

  [EN] CONJUGATES COMPRISING PHOSPHOANTIGENS AND THEIR USE IN THERAPY
  [FR] CONJUGUÉS COMPRENANT DES PHOSPHOANTIGÈNES ET LEUR UTILISATION À DES FINS THÉRAPEUTIQUES

  摘要：

  The present invention relates to novel conjugates comprising a targeting moiety linked to a phosphoantigen moiety, and the use thereof in the treatment of diseases, such as cancer, infectious diseases and autoimmune diseases, optionally in combination with other therapeutic agents. A targeting moiety may be an antibody, or binding fragment thereof. The phosphoantigen may be a prodrug. The invention further relates to linker-drug compounds comprising a phosphoantigen moiety, for use in the manufacture of conjugates, and pharmaceutical compositions comprising said immunoconjugates.

  公开号：

  WO2023275025A1

文献信息

• [EN] CONJUGATES COMPRISING PHOSPHOANTIGENS AND THEIR USE IN THERAPY<br/>[FR] CONJUGUÉS COMPRENANT DES PHOSPHOANTIGÈNES ET LEUR UTILISATION À DES FINS THÉRAPEUTIQUES
  申请人：[en]BYONDIS B.V.

  公开号：WO2023275025A1

  公开（公告）日：2023-01-05

  The present invention relates to novel conjugates comprising a targeting moiety linked to a phosphoantigen moiety, and the use thereof in the treatment of diseases, such as cancer, infectious diseases and autoimmune diseases, optionally in combination with other therapeutic agents. A targeting moiety may be an antibody, or binding fragment thereof. The phosphoantigen may be a prodrug. The invention further relates to linker-drug compounds comprising a phosphoantigen moiety, for use in the manufacture of conjugates, and pharmaceutical compositions comprising said immunoconjugates.